Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.

Autor: Haaland RE; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: hyw9@cdc.gov., Holder A; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: fka5@cdc.gov., Evans-Strickfaden T; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: tae0@cdc.gov., Nyagol B; KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: Bnyagol@kemricdc.org., Makanga M; KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: mmakanga@kemricdc.org., Oyaro B; KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: Boyaro@kemricdc.org., Humwa F; KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: FHumwa@kemricdc.org., Williams T; ICF International, Assigned to Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA 30329. Electronic address: wuq0@cdc.gov., McLellan-Lemal E; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: egm4@cdc.gov., Desai M; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: gdo5@cdc.gov., Huey MJ; Emory University Student Health Services, Emory University School of Medicine, 1525 Clifton Road, Atlanta, GA, USA 30322. Electronic address: mhuey@emory.edu.
Jazyk: angličtina
Zdroj: Contraception [Contraception] 2017 Jun; Vol. 95 (6), pp. 602-604. Date of Electronic Publication: 2017 Apr 01.
DOI: 10.1016/j.contraception.2017.03.011
Abstrakt: Objective: This study sought to measure residual contraceptive hormone levels in vaginal rings as an adherence marker for monitoring product use in clinical trials.
Study Design: Residual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were compared to those from 16 women who used NuvaRing® as their contraceptive choice.
Results: Twenty-one (81%) clinical trial rings had contraceptive hormone levels within the range of those used as a contraceptive choice. Five returned rings had unused or discordant levels of residual contraceptive hormones.
Conclusion: Residual vaginal ring drug levels could help assess adherence in clinical trials.
(Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: